Cadrenal Therapeutics Inc

NASDAQ:CVKDUnited States

Cadrenal Therapeutics, Inc. is a biopharmaceutical company. The Company is developing tecarfarin for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions. Tecarfarin has orphan drug and fast track designations from the United States Food and Drug Administration for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib). It is also pursuing additional regulatory strategies for unmet needs in anticoagulation therapy for patients with left ventricular assist devices (LVADs) and those with thrombotic antiphospholipid syndrome (APS). Tecarfarin is specifically designed to leverage a different metabolism pathway than the commonly prescribed Vitamin K Antagonist (warfarin).

Contact Information

Headquarters

822 A1a North, Suite 300PONTE VEDRA, FL, United States 32082

Phone

904-300-0701

Fax

302-655-5049

Executives

Chairman of the Board, Chief Executive Officer

Quang Pham

Chief Financial Officer

Matthew Szot

Chief Operating Officer

Jeffrey Cole

Chief Medical Officer

Douglas Losordo

Independent Director

Robert Lisicki